The Global Ophthalmic Disease Therapeutics Market will witness a steady growth due to the rise of ophthalmic diseases. According to a report published by Fortune Business Insights, titled “Ophthalmic Disease Therapeutics Market: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market was valued at US$ 29,504.8 Mn in 2018. Fortune Business Insights predicts that the global market will exhibit a CAGR of 6.1% and reach US$ 47,831.3 Mn by the end of 2026.
Browse Complete Report:
- Merck & Co. Inc.
- Pfizer Inc.
- Novartis AG
- Hoffmann-La Roche AG
- Regeneron Pharmaceuticals Inc
- Santen Pharmaceutical Co. Ltd
- Bayer AG
- Bausch & Lomb Inc
The National Eye Institute has projected that the rising population spends almost US$ 139 billion annually for vision disorders, and vision loss in the U.S. There has been an increasing number of cases of blindness around the world which is the main factor for the growth in the global ophthalmic disease therapeutics market. The renowned pharmaceutical companies are constantly investing in the R&D of therapies in order to treat retinal disorders. Retinal disorders are expected to witness advanced therapies that are yet to be approved in the near future. The report provides an in-depth analysis of various factors contributing to the growth of the global ophthalmic disease therapeutics market.
Anti-inflammatory Drugs to Lead the Global Ophthalmic Disease Therapeutics Market
The global ophthalmic disease therapeutics market consists of numerous drug classes. They are: anti-inflammatory, anti-glaucoma, anti-VEGF, anti-infectives, and others. Amongst these drug classes, anti-inflammatory drugs were leading the global ophthalmic disease therapeutics market in 2018 with an impressive market share of 25.5%. It is projected to remain dominant throughout the entire forecast period. Fortune Business Insights predicts that several other factors such as improved reimbursement policies for eye care, and corticosteroids in ocular diseases are likely to boost the segment’s market during 2019-2026.
Moreover, there is another drug class in the global ophthalmic disease therapeutics market called as the anti-VEGF. The usage of anti-VEGF prevents the growth of vascular permeability factor. It is projected that this particular segment will witness a high CAGR between 2019 and 2026. For improvement of anti-VEGF activities, clinical trials are being conducted regularly on novel molecules. This has resulted in an increasing number of clinical trials which is likely to boost the anti-VEGF segment during the forecast period.
Get Sample PDF:
Asia Pacific to Witness Growth of the Global Ophthalmic Disease Therapeutics Market
The launch of potent ophthalmic therapeutics in the U.S. for the betterments of ophthalmology outcomes is boosting the global ophthalmic disease therapeutics market in North America. There is another factor that has joined hands with the launch. Increasing number of retinal diseases in the region is also driving the market. In 2018, North America generated a value of USD 12,037.9 Mn, and the region was at the forefront of the global ophthalmic disease therapeutics market.
Europe is predicted to follow the footsteps of North America, and is expected to be the second-most leading region in the market as per revenue. Meanwhile, Asia Pacific is constantly improving when it comes to the distribution network of companies in the region. Hence, the region is slowly moving towards the growth of the global ophthalmic disease therapeutics market. Moreover, the government of the region is completely focusing on the diagnosis and prevention of blindness. This will also support the growth of the global ophthalmic disease therapeutics market with a significant CAGR by the end of 2026.
Hoffmann-La Roche AG, and Regeneron Pharmaceuticals Inc. to Lead the Market
The global ophthalmic disease therapeutics market is fragmented due to the entry of various small and mid-scale regional players. In May 2019, FDA approved Regeneron Pharmaceuticals Inc’s Eyelea injection for all stages of diabetic retinopathy as it is the major cause of vision loss in patients with diabetes. On the other hand, Lucentis by F. Hoffmann-La Roche AG is one of the most prominent therapies used for ophthalmic diseases namely macular edema, retinal vein occlusion and macular degeneration. These two products had generated a revenue of over US$ 5.0 Bn in 2018.
TABLE OF CONTENT:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions andAssumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1 Recent Industry Developments Such as Partnerships, Mergers & Acquisitions
4.2 Prevalence of Major Ophthalmic Diseases, in Key Countries, 2018
4.3 Pipeline Analysis
4.4 Patent Landscape
4.5 Reimbursement Scenario by Key Countries
4.6 Regulatory scenario for key countries
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
View Related Reports:
Point of Care Testing Market to Grow as New Home-Based Devices Gain Popularity Prominent Players: ARKRAY, Inc, Abaxis, Inc, Abbott, Alfa Scientific Designs, Inc, Ascencia Diabetes Care Holdings AG, Beckman Coulter